Buscar
Unicycive Therapeutics Inc
UNCYAñadir a la lista de seguimiento
5.010USD
-0.290-5.47%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
133.77MCap. mercado
PérdidaP/E TTM
Más Datos de Unicycive Therapeutics Inc Compañía
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Información de Unicycive Therapeutics Inc
Símbolo de cotizaciónUNCY
Nombre de la empresaUnicycive Therapeutics Inc
Fecha de salida a bolsaJun 17, 2021
Director ejecutivoGupta (Shalabh)
Número de empleados22
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 17
Dirección4300 El Camino Real, Suite 210
CiudadLOS ALTOS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94022
Teléfono16503840642
Sitio Webhttps://unicycive.com/
Símbolo de cotizaciónUNCY
Fecha de salida a bolsaJun 17, 2021
Director ejecutivoGupta (Shalabh)
Ejecutivos de Unicycive Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
+0.01%
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
+0.01%
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Unicycive Therapeutics Inc?
Los cinco principales accionistas de Unicycive Therapeutics Inc son: Dr. Sandeep (Steve) Laumas, M.D.
¿Cuántas instituciones poseen acciones de Unicycive Therapeutics Inc (UNCY)?
A fecha de 2026Q1, 75 instituciones poseen acciones de Unicycive Therapeutics Inc, con un valor de mercado combinado de aproximadamente 9.56M, lo que representa el 35.81% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 450872.00.